Revisiting patient protection in unproven cell and gene therapies under Japan's safety act

Japan's Act on the Safety of Regenerative Medicine entered into force in 2014 and was revised in 2025 to ensure the appropriate provision of unproven cell and gene therapies. However, two fatal cases occurred after the revision. This article examines practical challenges and proposes measures to better protect patient safety.